Skip to main content

Table 1 Inhibitory activity of BA and derivatives on different cancer cells proliferation

From: Design, synthesis and biological evaluation of novel betulinic acid derivatives

Compound IC50 (μM) a values against five human carcinoma cells
  MGC-803b PC3c A375d Bcap-37e A431f
1 41.2 ± 0.6 67.2 ± 0.5 > 100 > 100 15.7 ± 0.2
2a > 20 > 20 > 20 > 20 > 20
2b > 20 > 20 > 20 > 20 > 20
2c > 20 > 20 > 20 > 20 > 20
3a 3.5 ± 0.5 5.6 ± 0.9 3.4 ± 0.1 5.5 ± 0.8 4.8 ± 0.2
3b 3.4 ± 0.2 4.2 ± 0.2 6.0 ± 0.4 7.6 ± 0.5 5.7 ± 0.2
3c 2.3 ± 0.2 4.6 ± 0.5 3.3 ± 0.4 3.6 ± 1.2 4.3 ± 0.3
3d 7.6 ± 2.1 8.6 ± 0.2 12.4 ± 1.1 10.5 ± 0.5 11.8 ± 0.6
3e 4.0 ± 0.9 3.8 ± 1.1 4.4 ± 0.5 3.0 ± 1.1 5.6 ± 0.1
3f 4.3 ± 0.2 2.8 ± 0.4 2.7 ± 0.3 5.2 ± 0.1 3.5 ± 0.6
3g 15.7 ± 0.5 13.4 ± 0.9 11.3 ± 0.6 16.2 ± 0.5 13.3 ± 0.4
3h 12.7 ± 1.2 15.0 ± 0.5 11.6 ± 0.5 12.5 ± 0.5 9.6 ± 0.9
3i 5.6 ± 0.4 7.9 ± 0.5 7.7 ± 0.3 6.8 ± 1.2 5.7 ± 0.2
3j 7.6 ± 0.6 13.4 ± 0.7 12.8 ± 0.4 7.5 ± 0.6 10.5 ± 1.5
3k 16.7 ± 0.5 17.1 ± 0.2 > 20 > 20 15.7 ± 0.7
3l 11.8 ± 0.3 12.7 ± 1.5 13.9 ± 0.8 9.43 ± 0.8 7.0 ± 0.4
5a 8.8 ± 0.8 10.1 ± 0.5 12.5 ± 0.6 9.4 ± 0.7 6.3 ± 0.8
5b 13.4 ± 0.1 14.5 ± 0.4 15.3 ± 2.3 16.7 ± 0.8 12.9 ± 1.2
5c 17.3 ± 0.4 > 20 > 20 > 20 > 20
5d > 20 18.9 ± 0.3 > 20 > 20 16.3 ± 0.1
5e > 20 > 20 > 20 > 20 > 20
5f 15.4 ± 0.6 > 20 > 20 > 20 > 20
HCPT 29.1 ± 2.6 34.5 ± 1.5 27.8 ± 1.2 28.1 ± 1.0 23.4 ± 0.7
ADM 0.7 ± 0.2 0.6 ± 0.1 1.0 ± 0.6 1.2 ± 0.2 1.1 ± 0.1
  1. a Agent concentration (micromolar) that inhibited cell growth by 50% 72 h after treatment; b Human gastric cancer; c Prostate cancer; d Malignant melanoma; e Breast cancer; f Epidermoid carcinoma.